Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

What’s Going On With ShiftPixy Shares?

ShiftPixy, Inc. (NASDAQ: PIXY) shares are climbing on Friday following a week of volitile trading and massive price moves. What To Know:
byErica Kollmann
June 23, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

ShiftPixy, Inc. (NASDAQ:PIXY) shares are climbing on Friday following a week of volitile trading and massive price moves.

What To Know:

Shares of ShiftPixy are moving higher on continued high trading volume. Volume on Friday has already topped the 1.7 million mark, doubling the stock's 100-day average of 806,000 shares traded.

According to Benzinga Pro, over 10% of available shares are currently sold short which may be contributing to the stock’s recent price fluctuations. The stock has a float of 1.502 million.

ShiftPixy provides payroll and human resource solutions for hospitality-centered businesses and workers in the gig economy.

Related News: Why Applied Digital Shares Are Skyrocketing Today

PIXY Price Action: According to Benzinga Pro, ShiftPixy shares are trading 5% higher at $2.11 at the time of publication.

Image: sergeitokmakov from Pixabay

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

US Stocks Could Lose Momentum Thursday As Futures Trade Flat Ahead Of Powell Speech — Tesla, GameStop In Focus

By Shanthi Rexaline
September 8, 6:56 AM
The major U.S. index futures are little changed on Thursday, as apprehensions return after Wednesday’s strong advances. Investors are left to contend with more Fed speeches, while the corporate news flow remains fairly light. On Wednesday, U.S. stocks opened mostly higher and stayed above the unchanged line for the bulk of the session, before closing notably higher.

BILI

Read More

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Avi Kapoor
December 11, 2:12 PM
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

AAGR